CareFirst Family of health care plans

CVS caremark™

PRIOR AUTHORIZATION CRITERIA

BRAND NAME
(generic)

LIDODERM
(lidocaine patch 5%)

Status: CVS Caremark Criteria
Type: Initial Prior Authorization with Quantity Limit

POLICY

FDA-APPROVED INDICATIONS

Lidoderm is indicated for relief of pain associated with post-herpetic neuralgia. It should be applied only to **intact skin**.

Compendial Uses

Pain associated with diabetic neuropathy
Pain associated with cancer-related neuropathy

COVERAGE CRITERIA

The requested drug will be covered with prior authorization when the following criteria are met:

- The requested drug is being prescribed for any of the following:
  - Pain associated with post-herpetic neuralgia
  - Pain associated with diabetic neuropathy
  - Pain associated with cancer-related neuropathy (including treatment-related neuropathy [e.g. neuropathy associated with radiation treatment or chemotherapy]).

Quantity Limits apply.
90 patches/25 days*
270 patches/75 days*
**The duration of 25 days is used for a 30-day fill period and 75 days is used for a 90-day fill period to allow time for refill processing.*

REFERENCES

1. Lidoderm [package insert]. Chadds Ford, PA: Endo Pharmaceuticals Inc.; January 2015.
2. AHFS DI (Adult and Pediatric) [database online]. Hudson, OH: Lexi-Comp, Inc.; http://online.lexi.com/lco/action/index/dataset/complete_ashp [available with subscription]. Accessed September 2017.
3. Micromedex Solutions [database online]. Greenwood Village, CO: Truven Health Analytics Inc. Updated periodically. www.micromedexsolutions.com [available with subscription]. Accessed September 2017.
4. Barbano RL, Herrmann DN, Hart-Gouleau S, et al: Effectiveness, tolerability, and impact on quality of life of the 5% lidocaine patch in diabetic polyneuropathy. Arch Neurol 2004; 61:914-918.
5. Dworkin RH, O'Connor AB, Backonja M, et al. Pharmacologic Management of Neuropathic Pain: Evidence-based Recommendations. *Pain* 2007; 132(3):237-251.
6. National Comprehensive Cancer Network: Adult Cancer Pain V.2.2017. National Comprehensive Cancer Network. Fort Washington, PA. 2008. Available from URL: http://www.nccn.org/professionals/physician_gls/PDF/pain.pdf. Accessed September 2017.

7. Vadalouca A, Raptis E, Moka E, et al. Pharmacological Treatment of Neuropathic Cancer Pain: A Comprehensive Review of Current Literature. World Institute of Pain. *Pain Practice.* 2011; 12(3):219-251.